{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:13:17Z","timestamp":1761959597069,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":226,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2022.100345","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:21:15Z","timestamp":1660746075000},"page":"100345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-3171","authenticated-orcid":false,"given":"Hamid","family":"Ehsan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qamar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Masood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lrr.2022.100345_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lrr.2022.100345_bib0002","unstructured":"SEER cancer statistics review, 1975-2016. [Internet]. 2018 [cited October 2021]. Available from: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2016\/#citation."},{"issue":"15","key":"10.1016\/j.lrr.2022.100345_bib0003","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lrr.2022.100345_bib0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21556660.2018.1492925","article-title":"Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)","volume":"7","author":"Acharya","year":"2018","journal-title":"J. Drug Assess."},{"issue":"7","key":"10.1016\/j.lrr.2022.100345_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254976","article-title":"Survival prognostic factors in patients with acute myeloid leukemia using machine learning techniques","volume":"16","author":"Karami","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lrr.2022.100345_bib0006","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2022.100345_bib0007","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lrr.2022.100345_bib0008","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lrr.2022.100345_bib0009","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2022.100345_bib0010","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S2152-2650(21)01697-9","article-title":"AML-212: Treatment Free Remission (TFR) after ceasing venetoclax-based therapy in responding patients with acute myeloid leukemia","volume":"21","author":"Chua","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.lrr.2022.100345_bib0011","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.13062","article-title":"Persistence of DNMT3A mutations at long-term remission in adult patients with AML","volume":"167","author":"Pl\u00f8en","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.lrr.2022.100345_bib0012","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:59Z","timestamp":1761959339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048922000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":12,"alternative-id":["S2213048922000577"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100345","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100345"}}